Skip to main content
. Author manuscript; available in PMC: 2011 Feb 15.
Published in final edited form as: Cancer. 2010 Feb 15;116(4 Suppl):1134–1145. doi: 10.1002/cncr.24802

Figure 2.

Figure 2

90Y-veltuzumab therapy with consolidation veltuzumab therapy. Nude mice bearing s.c. Ramos tumors were given 90Y-veltuzumab alone (0.13 mCi/0.05 mg), or a reduced veltuzumab pre-dose of 0.25 mg was given 1 day before receiving 90Y-veltuzumab, and another group received the pre-dose, as well as a veltuzumab consolidation therapy starting 1 week after the radioconjugate using 1.0 mg veltuzumab followed by 3 more weekly injections of 0.5 mg veltuzumab. Survival based on time to progression to 3.0 cm3.